ClearNote Health has announced that its Avantect test could detect pancreatic cancer in high-risk patients, such as those diagnosed with Type 2 diabetes recently, in a study.

The company revealed the data from the study ‘Epigenomic Blood-based Early Detection of Pancreatic Cancer Employing Cell-free DNA.’

The Avantect Pancreatic Cancer Test primarily assesses alterations in 5-hydroxymethylcytosine (5hmC) signals in cell-free DNA obtained from plasma.

According to the company, the study is designed to describe the DNA-based blood test’s development and validation.

The case-control validation study, which involved 2,150 patient samples, indicated high specificity of 96.9% and early-stage (Stage I/II) sensitivity of 68.3%.

ClearNote Health chief scientific officer Samuel Levy said: “Our unique approach to early detection combines epigenomics with genomic alterations and fragmentomics as input to sophisticated machine learning algorithms.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“This enables us to offer clinicians an early detection test that can be used to guide patient management recommendations and identify pancreatic cancers at early, treatable stages when longer-term patient survival is still possible.”

The test is supported by the company’s automated, 5hmC-based epigenomic platform, which measures active biological events that take place in tumours during the early stages of cancer formation.

This platform enhances DNA fragments through 5hmC labelling to target a subset of dynamically demethylated bases.

Furthermore, the new data confirm that the company’s epigenomic platform is useful for detecting cancer in individuals who are at a higher risk of developing pancreatic cancer. It enables timely detection and intervention of the disease.